Benutzer: Gast  Login
Titel:

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Dokumenttyp:
Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article
Autor(en):
Döhner, Hartmut; Weber, Daniela; Krzykalla, Julia; Fiedler, Walter; Kühn, Michael W M; Schroeder, Thomas; Mayer, Karin; Lübbert, Michael; Wattad, Mohammed; Götze, Katharina; Fransecky, Lars; Koller, Elisabeth; Wulf, Gerald; Schleicher, Jan; Ringhoffer, Mark; Greil, Richard; Hertenstein, Bernd; Krauter, Jürgen; Martens, Uwe M; Nachbaur, David; Samra, Maisun Abu; Machherndl-Spandl, Sigrid; Basara, Nadezda; Leis, Claudia; Schrade, Anika; Kapp-Schwoerer, Silke; Cocciardi, Sibylle; Bullinger, Lars; T...     »
Abstract:
BACKGROUND: Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin in participants with newly diagnosed, NPM1-mutated acute myeloid leukaemia. METHODS: This open-label, phase 3 trial was conducted at 56 hospitals in Germany and Austria. Eligible participants were 18 years or older and had newly diag...     »
Zeitschriftentitel:
Lancet Haematol
Jahr:
2023
Band / Volume:
10
Heft / Issue:
7
Seitenangaben Beitrag:
e495-e509
Volltext / DOI:
doi:10.1016/S2352-3026(23)00089-3
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/37187198
TUM Einrichtung:
290; Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)
 BibTeX